Smital Shah's most recent trade in Lyell Immunopharma Inc was a trade of 140,000 Option (right to buy) done . Disclosure was reported to the exchange on March 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Smital Shah | Chief Fin. and Bus. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2026 | 140,000 | 140,000 | - | - | Option (right to buy) | |
| Pliant Therapeutics Inc | Smital Shah | Director | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | ||
| Graphite Bio Inc | Smital Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Smital Shah | Director | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | ||
| Graphite Bio Inc | Smital Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | Smital Shah | Director | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |